Thus, even though ozoralizumab was administered to the mice that had generated ADAs against adalimumab, ADAs were not generated against ozoralizumab, and as a result switching to ozoralizumab was capable of continuing to suppress the arthritis. This evidence concerns the gene AGPS and arthritic joint disease.